US 12,263,178 B2
Pharmaceutical compositions and methods
Randice Lisa Altshul, Cliffside Park, NJ (US); Neil David Thiese, New York, NY (US); Andreas J. Kesel, Munich (DE); Myron Rapkin, Indianapolis, IN (US); Rebecca O'Brien, Shell Knob, MO (US); and Anthony Arment, Fairborn, OH (US)
Assigned to Pop Test Oncology LLC, Cliffside Park, NJ (US)
Filed by Pop Test Oncology LLC, Cliffside Park, NJ (US)
Filed on Oct. 31, 2022, as Appl. No. 17/977,371.
Application 16/242,273 is a division of application No. 15/825,982, filed on Nov. 29, 2017, granted, now 10,238,666, issued on Mar. 26, 2019.
Application 15/825,982 is a division of application No. 15/370,680, filed on Dec. 6, 2016, granted, now 9,855,284, issued on Jan. 2, 2018.
Application 15/370,680 is a division of application No. 15/222,062, filed on Jul. 28, 2016, granted, now 9,598,459, issued on Mar. 21, 2017.
Application 17/977,371 is a continuation of application No. 16/690,282, filed on Nov. 21, 2019, granted, now 11,576,921.
Application 16/690,282 is a continuation of application No. 16/242,273, filed on Jan. 8, 2019, granted, now 10,517,881, issued on Dec. 31, 2019.
Claims priority of provisional application 62/361,125, filed on Jul. 12, 2016.
Claims priority of provisional application 62/358,211, filed on Jul. 5, 2016.
Claims priority of provisional application 62/352,572, filed on Jun. 21, 2016.
Claims priority of provisional application 62/352,611, filed on Jun. 21, 2016.
Claims priority of provisional application 62/352,576, filed on Jun. 21, 2016.
Claims priority of provisional application 62/352,624, filed on Jun. 21, 2016.
Claims priority of provisional application 62/349,235, filed on Jun. 13, 2016.
Claims priority of provisional application 62/345,095, filed on Jun. 3, 2016.
Claims priority of provisional application 62/345,319, filed on Jun. 3, 2016.
Claims priority of provisional application 62/342,967, filed on May 29, 2016.
Claims priority of provisional application 62/342,965, filed on May 29, 2016.
Claims priority of provisional application 62/342,966, filed on May 29, 2016.
Claims priority of provisional application 62/342,103, filed on May 26, 2016.
Claims priority of provisional application 62/339,906, filed on May 22, 2016.
Claims priority of provisional application 62/339,909, filed on May 22, 2016.
Claims priority of provisional application 62/314,046, filed on Mar. 28, 2016.
Claims priority of provisional application 62/299,120, filed on Feb. 24, 2016.
Claims priority of provisional application 62/296,673, filed on Feb. 18, 2016.
Claims priority of provisional application 62/280,073, filed on Jan. 18, 2016.
Claims priority of provisional application 62/271,038, filed on Dec. 22, 2015.
Claims priority of provisional application 62/241,875, filed on Oct. 15, 2015.
Claims priority of provisional application 62/220,583, filed on Sep. 18, 2015.
Claims priority of provisional application 62/282,525, filed on Aug. 3, 2015.
Prior Publication US 2023/0142627 A1, May 11, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 407/14 (2006.01); A61K 31/485 (2006.01); A61K 31/513 (2006.01); A61K 31/57 (2006.01); A61K 31/58 (2006.01); A61K 31/7068 (2006.01); A61K 45/06 (2006.01); C07H 19/06 (2006.01); C07H 19/067 (2006.01); C07J 17/00 (2006.01); C07J 41/00 (2006.01)
CPC A61K 31/58 (2013.01) [A61K 31/485 (2013.01); A61K 31/513 (2013.01); A61K 31/57 (2013.01); A61K 31/7068 (2013.01); A61K 45/06 (2013.01); C07H 19/06 (2013.01); C07H 19/067 (2013.01); C07J 17/00 (2013.01); C07J 41/0005 (2013.01)] 14 Claims
 
1. A pharmaceutical composition comprising:
at least one active agent selected from the group consisting of PT155, PT156, PT157, PT158, TCY1, combinations thereof, and pharmaceutically acceptable salts thereof;
optionally, at least one auxiliary agent selected from the group consisting of oxycodone, hydrocodone, hydromorphone and methadone.